The beneficial effects of statins in patients undergoing hemodialysis

International Journal of Cardiology

Volumn 168, Issue 4, 2013, Pages 4155-4159

  Chen, Jaw Wen ^a,b   Huang, Chin Chou ^a,b   Chan, Wan Leong ^a   Chen, Yu Chun ^a,b   Chen, Tzeng Ji ^a,b   Chung, Chia Min ^c   Huang, Po Hsun ^a,b   Lin, Shing Jong ^a,b   Leu, Hsin Bang ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

Cardiovascular; Hemodialysis; Morbidity; Mortality; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TICLOPIDINE; WARFARIN;

ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFECT; DRUG USE; FEMALE; HEMODIALYSIS PATIENT; HOSPITALIZATION; HUMAN; KIDNEY FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; RISK REDUCTION; TAIWAN; UNSTABLE ANGINA PECTORIS;

CARDIOVASCULAR; HEMODIALYSIS; MORBIDITY; MORTALITY; STATINS;

ADULT; AGED; CARDIOVASCULAR DISEASES; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; RENAL DIALYSIS; TAIWAN; TREATMENT OUTCOME;

EID: 84886242785     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.07.115     Document Type: Article

References (30)

1. M.J. Lysaght Maintenance dialysis population dynamics: current trends and long-term implications J Am Soc Nephrol 13 2002 S37 S40
2. J. Coresh, E. Selvin, and L.A. Stevens Prevalence of chronic kidney disease in the United States JAMA 298 2007 2038 2047
3. U.S. Renal Data System USRDS 2009 annual data report: volume three: reference tables on end-stage renal disease, section D: treatment modalities 2009 National Institute of Health, National Institute of Diabetes and Digestive and Kidney Disease Bethesda, MD 510
4. H.W. Kuo, S.S. Tsai, M.M. Tiao, and C.Y. Yang Epidemiological features of CKD in Taiwan Am J Kidney Dis 49 2007 46 55
5. C.P. Wen, T.Y. Cheng, and M.K. Tsai All-cause mortality attributable to chronic kidney disease: a prospective cohort study based on 462 293 adults in Taiwan Lancet 371 2008 2173 2182
6. C. Baigent, K. Burbury, and D. Wheeler Premature cardiovascular disease in chronic renal failure Lancet 356 2000 147 152
7. Cholesterol Treatment Trialists' (CTT) Collaboration C. Baigent, and L. Blackwell Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
8. J.C. LaRosa, J. He, and S. Vupputuri Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials JAMA 282 1999 2340 2346
9. J. Shepherd, S.M. Cobbe, and I. Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Group N Engl J Med 333 1995 1301 1307
10. M. Briel, M. Studer, T.R. Glass, and H.C. Bucher Effects of statins on stroke prevention in patients with and without coronary heart disease: a meta-analysis of randomized controlled trials Am J Med 117 2004 596 606
11. P. Amarenco, J. Labreuche, P. Lavallée, and P.J. Touboul Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis Stroke 35 2004 2902 2909
12. N.A. Mason, G.R. Bailie, and S. Satayathum HMG-CoA reductase inhibitor use is associated with mortality reduction in hemodialysis patients Am J Kidney Dis 45 2005 119 126
13. C. Wanner, V. Krane, and W. März Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248
14. B.C. Fellström, A.G. Jardine, and R.E. Schmieder Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 2009 1395 1407
15. Bureau of National Health Insurance 2001 national health insurance annual statistical report 2002 Bureau of National Health Insurance Taipei, Taiwan
16. WHO Collaborating Center for Drug Statistics Methodology ATC index with DDDs 2003 2003 WHO Oslo
17. N.I. Parikh, S.J. Hwang, M.G. Larson, J.B. Meigs, D. Levy, and C.S. Fox Cardiovascular disease risk factors in chronic kidney disease: overall burden and rates of treatment and control Arch Intern Med 166 2006 1884 1891
18. G.F. Strippoli, S.D. Navaneethan, and D.W. Johnson Effects of statins in patients with chronic kidney disease: meta-analysis and metaregression of randomised controlled trials BMJ 336 2008 645 651
19. C. Baigent, M.J. Landray, and C. Reith The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial Lancet 377 2011 2181 2192
20. D. Kirmizis, A. Papagianni, and F. Dogrammatzi Effects of simvastatin on markers of inflammation, oxidative stress and endothelial cell apoptosis in patients on chronic hemodialysis J Atheroscler Thromb 17 2010 1256 1265
21. W. März, B. Genser, and C. Drechsler Atorvastatin and low-density lipoprotein cholesterol in type 2 diabetes mellitus patients on hemodialysis Clin J Am Soc Nephrol 6 2011 1316 1325
22. H. Holdaas, I. Holme, and R.E. Schmieder Rosuvastatin in diabetic hemodialysis patients J Am Soc Nephrol 22 2011 1335 1341
23. D. Grady, N.K. Wenger, and D. Herrington Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study Ann Intern Med 132 2000 689 696
24. J.G. Ray, M. Mamdani, R.T. Tsuyuki, D.R. Anderson, E.L. Yeo, and A. Laupacis Use of statins and the subsequent development of deep vein thrombosis Arch Intern Med 161 2001 1405 1410
25. C.J. Doggen, R.N. Lemaitre, N.L. Smith, S.R. Heckbert, and B.M. Psaty HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women J Thromb Haemost 2 2004 700 701
26. J. Himmelfarb, P. Stenvinkel, T.A. Ikizler, and R.M. Hakim The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia Kidney Int 62 2002 1524 1538
27. F. Arslan, G. Pasterkamp, and D.P. de Kleijn Unraveling pleiotropic effects of statins: bit by bit, a slow case with perspective Circ Res 103 2008 334 336
28. A. Undas, K.E. Brummel-Ziedins, and K.G. Mann Statins and blood coagulation Arterioscler Thromb Vasc Biol 25 2005 287 294
29. M.N. Lai, J.N. Lai, P.C. Chen, S.C. Hsieh, F.C. Hu, and J.D. Wang Risks of kidney failure associated with consumption of herbal products containing Mu Tong or Fangchi: a population-based case-control study Am J Kidney Dis 55 2010 507 518
30. J.C. Luo, H.B. Leu, and K.W. Huang Incidence of bleeding from gastroduodenal ulcers in patients with end-stage renal disease receiving hemodialysis CMAJ 183 2011 E1345 E1351